Study 205 schema
A multicenter, randomized, phase 2 trial in patients with advanced or metastatic renal cell carcinoma (RCC) who had previously received anti-angiogenic therapy1
aPatients were stratified by hemoglobin level (≤13 g/dL vs >13 g/dL for males and ≤11.5 g/dL vs >11.5 g/dL for females) and corrected serum calcium (≥10 mg/dL vs <10 mg/dL).
bInvestigator-assessed and evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Key inclusion criteria1
Patients were required to have
- histological confirmation of clear cell RCC
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1